Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Study of Capmatinib in cMET-dependent Malignancies
2024-510948-31-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of capmatinib in cancer, sponsored by Novartis. Primary endpoint: Safety: Frequency and severity of adverse events and serious adverse events. Planned start Jun 2024; status: authorised.
02
Drugs
capmatinib
03
Conditions
cancer
Beyond the preview
Go deeper on 2024-510948-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510948-31-00.